PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1377457-7	1992	The acute phase reaction of factor VIII coagulant and von Willebrand factor, which plays a role in postoperative hypercoagulability, was attenuated by the use of HES.	Hydroxyethyl Starch Derivatives	162-165	von Willebrand factor	Homo sapiens	54-75	
9140565-9	1997	Prothrombin time, APTT, and fibrinogen concentrations decreased after infusions and vWf:Ag and FVIII:C activities were decreased in dose-dependent manner in HES-treated ponies.	Hydroxyethyl Starch Derivatives	157-160	von Willebrand factor	Homo sapiens	84-87	
19825916-3	2010	RESULTS: Group HES and GEL had significantly prolonged PT and aPTT, decreased VIII:C and vWF immediately after AHFI.	Hydroxyethyl Starch Derivatives	15-18	von Willebrand factor	Homo sapiens	89-92	
18633012-9	2008	In the early postoperative phase, HES 130/0.4 was found to exert significantly less effect on measures of coagulation, especially activated partial thromboplastin time and von Willebrand factor (antigen and ristocetin cofactor), than HES 200/0.5.	Hydroxyethyl Starch Derivatives	34-37	von Willebrand factor	Homo sapiens	172-193	
17122237-10	2006	CONCLUSIONS: Patients with Type O blood may have increased coagulation compromise, and greater dilution of Factor VIII activity, vWF:ag, and vWF:RCof after acute normovolemic hemodilution with HES.	Hydroxyethyl Starch Derivatives	193-196	von Willebrand factor	Homo sapiens	141-144	
11375811-6	2001	The decrease in VIII/vWF complex was proportional to the volume of infused HES (20 and 30 mL/kg) and was more pronounced in patients of the O blood group.	Hydroxyethyl Starch Derivatives	75-78	von Willebrand factor	Homo sapiens	21-24